Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Cognitive Correlates of MRI-defined Cerebral Vascular Injury and Atrophy in Elderly American Indians: The Strong Heart Study.

Suchy-Dicey A, Shibata D, Cholerton B, Nelson L, Calhoun D, Ali T, Montine TJ, Longstreth WT, Buchwald D, Verney SP.

J Int Neuropsychol Soc. 2019 Dec 3:1-13. doi: 10.1017/S1355617719001073. [Epub ahead of print]

PMID:
31791442
2.

Cognitive associations with comprehensive gait and static balance measures in Parkinson's disease.

Morris R, Martini DN, Smulders K, Kelly VE, Zabetian CP, Poston K, Hiller A, Chung KA, Yang L, Hu SC, Edwards KL, Cholerton B, Grabowski TJ, Montine TJ, Quinn JF, Horak F.

Parkinsonism Relat Disord. 2019 Jul 4;69:104-110. doi: 10.1016/j.parkreldis.2019.06.014. [Epub ahead of print]

PMID:
31731260
3.

The associations among sociocultural factors and neuropsychological functioning in older American Indians: The Strong Heart Study.

Verney SP, Suchy-Dicey AM, Cholerton B, Calhoun D, Nelson L, Montine TJ, Ali T, Longstreth WT, Buchwald D.

Neuropsychology. 2019 Nov;33(8):1078-1088. doi: 10.1037/neu0000574. Epub 2019 Jul 25.

PMID:
31343235
4.

Visuospatial functioning is associated with sleep disturbance and hallucinations in nondemented patients with Parkinson's disease.

Specketer K, Zabetian CP, Edwards KL, Tian L, Quinn JF, Peterson-Hiller AL, Chung KA, Hu SC, Montine TJ, Cholerton BA.

J Clin Exp Neuropsychol. 2019 Oct;41(8):803-813. doi: 10.1080/13803395.2019.1623180. Epub 2019 Jun 10.

PMID:
31177941
5.

Type 2 diabetes and later cognitive function in older American Indians: The Strong Heart Study.

Cholerton B, Omidpanah A, Verney SP, Nelson LA, Baker LD, Suchy-Dicey A, Longstreth WT Jr, Howard BV, Henderson JA, Montine TJ, Buchwald D.

Int J Geriatr Psychiatry. 2019 Jul;34(7):1050-1057. doi: 10.1002/gps.5108. Epub 2019 Apr 15.

PMID:
30924200
6.

Cognitive Performance in Parkinson's Disease in the Brain Health Registry.

Cholerton B, Weiner MW, Nosheny RL, Poston KL, Mackin RS, Tian L, Ashford JW, Montine TJ.

J Alzheimers Dis. 2019;68(3):1029-1038. doi: 10.3233/JAD-181009.

7.

Using Varying Diagnostic Criteria to Examine Mild Cognitive Impairment Prevalence and Predict Dementia Incidence in a Community-Based Sample.

Robertson K, Larson EB, Crane PK, Cholerton B, Craft S, McCormick WC, McCurry SM, Bowen JD, Baker LD, Trittschuh EH.

J Alzheimers Dis. 2019;68(4):1439-1451. doi: 10.3233/JAD-180746.

PMID:
30909213
8.

Concepts for brain aging: resistance, resilience, reserve, and compensation.

Montine TJ, Cholerton BA, Corrada MM, Edland SD, Flanagan ME, Hemmy LS, Kawas CH, White LR.

Alzheimers Res Ther. 2019 Mar 11;11(1):22. doi: 10.1186/s13195-019-0479-y.

9.

An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele.

Shahid M, Kim J, Leaver K, Hendershott T, Zhu D, Cholerton B, Henderson VW, Tian L, Poston KL.

Neurobiol Dis. 2019 Jul;127:278-286. doi: 10.1016/j.nbd.2019.02.023. Epub 2019 Feb 28.

PMID:
30826425
10.

Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease.

Hendershott TR, Zhu D, Llanes S, Zabetian CP, Quinn J, Edwards KL, Leverenz JB, Montine T, Cholerton B, Poston KL.

Mov Disord. 2019 Feb;34(2):285-291. doi: 10.1002/mds.27575. Epub 2018 Dec 10.

PMID:
30776152
11.

TDP-43 Neuropathologic Associations in the Nun Study and the Honolulu-Asia Aging Study.

Flanagan ME, Cholerton B, Latimer CS, Hemmy LS, Edland SD, Montine KS, White LR, Montine TJ.

J Alzheimers Dis. 2018;66(4):1549-1558. doi: 10.3233/JAD-180162.

12.

Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease.

Cholerton B, Johnson CO, Fish B, Quinn JF, Chung KA, Peterson-Hiller AL, Rosenthal LS, Dawson TM, Albert MS, Hu SC, Mata IF, Leverenz JB, Poston KL, Montine TJ, Zabetian CP, Edwards KL.

Parkinsonism Relat Disord. 2018 May;50:29-36. doi: 10.1016/j.parkreldis.2018.02.007. Epub 2018 Feb 9.

13.

Quantitative cerebrovascular pathology in a community-based cohort of older adults.

Rane S, Koh N, Boord P, Madhyastha T, Askren MK, Jayadev S, Cholerton B, Larson E, Grabowski TJ.

Neurobiol Aging. 2018 May;65:77-85. doi: 10.1016/j.neurobiolaging.2018.01.006. Epub 2018 Jan 31.

14.

Associations between Use of Specific Analgesics and Concentrations of Amyloid-β 42 or Phospho-Tau in Regions of Human Cerebral Cortex.

Flanagan ME, Larson EB, Walker RL, Keene CD, Postupna N, Cholerton B, Sonnen JA, Dublin S, Crane PK, Montine TJ.

J Alzheimers Dis. 2018;61(2):653-662. doi: 10.3233/JAD-170414.

15.

Homocysteine and cognitive function in Parkinson's disease.

Licking N, Murchison C, Cholerton B, Zabetian CP, Hu SC, Montine TJ, Peterson-Hiller AL, Chung KA, Edwards K, Leverenz JB, Quinn JF.

Parkinsonism Relat Disord. 2017 Nov;44:1-5. doi: 10.1016/j.parkreldis.2017.08.005. Epub 2017 Aug 9.

16.

Total Brain and Hippocampal Volumes and Cognition in Older American Indians: The Strong Heart Study.

Cholerton B, Omidpanah A, Madhyastha TM, Grabowski TJ, Suchy-Dicey AM, Shibata DK, Nelson LA, Verney SP, Howard BV, Longstreth WT Jr, Montine TJ, Buchwald D.

Alzheimer Dis Assoc Disord. 2017 Apr-Jun;31(2):94-100. doi: 10.1097/WAD.0000000000000203.

17.

Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease.

Mata IF, Johnson CO, Leverenz JB, Weintraub D, Trojanowski JQ, Van Deerlin VM, Ritz B, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson-Hiller AL, Espay AJ, Revilla FJ, Devoto J, Yearout D, Hu SC, Cholerton BA, Montine TJ, Edwards KL, Zabetian CP.

Neurobiol Aging. 2017 Aug;56:211.e1-211.e7. doi: 10.1016/j.neurobiolaging.2017.04.009. Epub 2017 Apr 20.

18.

Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial.

Craft S, Claxton A, Baker LD, Hanson AJ, Cholerton B, Trittschuh EH, Dahl D, Caulder E, Neth B, Montine TJ, Jung Y, Maldjian J, Whitlow C, Friedman S.

J Alzheimers Dis. 2017;57(4):1325-1334. doi: 10.3233/JAD-161256.

19.

The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot.

Mata IF, Davis MY, Lopez AN, Dorschner MO, Martinez E, Yearout D, Cholerton BA, Hu SC, Edwards KL, Bird TD, Zabetian CP.

Am J Med Genet B Neuropsychiatr Genet. 2017 Jan;174(1):113. doi: 10.1002/ajmg.b.32510. Epub 2016 Dec 1. No abstract available.

PMID:
27943640
20.

Type 2 Diabetes, Cognition, and Dementia in Older Adults: Toward a Precision Health Approach.

Cholerton B, Baker LD, Montine TJ, Craft S.

Diabetes Spectr. 2016 Nov;29(4):210-219.

21.

Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease.

Davis MY, Johnson CO, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Quinn JF, Chung KA, Peterson-Hiller AL, Rosenthal LS, Dawson TM, Albert MS, Goldman JG, Stebbins GT, Bernard B, Wszolek ZK, Ross OA, Dickson DW, Eidelberg D, Mattis PJ, Niethammer M, Yearout D, Hu SC, Cholerton BA, Smith M, Mata IF, Montine TJ, Edwards KL, Zabetian CP.

JAMA Neurol. 2016 Oct 1;73(10):1217-1224. doi: 10.1001/jamaneurol.2016.2245.

22.

The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot.

Mata IF, Davis MY, Lopez AN, Dorschner MO, Martinez E, Yearout D, Cholerton BA, Hu SC, Edwards KL, Bird TD, Zabetian CP.

Am J Med Genet B Neuropsychiatr Genet. 2016 Oct;171(7):925-30. doi: 10.1002/ajmg.b.32452. Epub 2016 Apr 25. Erratum in: Am J Med Genet B Neuropsychiatr Genet. 2017 Jan;174(1):113.

23.

Precision Medicine: Clarity for the Complexity of Dementia.

Cholerton B, Larson EB, Quinn JF, Zabetian CP, Mata IF, Keene CD, Flanagan M, Crane PK, Grabowski TJ, Montine KS, Montine TJ.

Am J Pathol. 2016 Mar;186(3):500-6. doi: 10.1016/j.ajpath.2015.12.001. Epub 2015 Dec 24. Review.

24.

Screening of cognitive impairment in patients with Parkinson's disease: diagnostic validity of the Brazilian versions of the Montreal Cognitive Assessment and the Addenbrooke's Cognitive Examination-Revised.

Sobreira E, Pena-Pereira MA, Eckeli AL, Sobreira-Neto MA, Chagas MH, Foss MP, Cholerton B, Zabetian CP, Mata IF, Tumas V.

Arq Neuropsiquiatr. 2015 Nov;73(11):929-33. doi: 10.1590/0004-282X20150156.

25.

Differential Effects of Meal Challenges on Cognition, Metabolism, and Biomarkers for Apolipoprotein E ɛ4 Carriers and Adults with Mild Cognitive Impairment.

Hanson AJ, Bayer JL, Baker LD, Cholerton B, VanFossen B, Trittschuh E, Rissman RA, Donohue MC, Moghadam SH, Plymate SR, Craft S.

J Alzheimers Dis. 2015;48(1):205-18. doi: 10.3233/JAD-150273.

PMID:
26401941
26.

The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease.

Mata IF, Jang Y, Kim CH, Hanna DS, Dorschner MO, Samii A, Agarwal P, Roberts JW, Klepitskaya O, Shprecher DR, Chung KA, Factor SA, Espay AJ, Revilla FJ, Higgins DS, Litvan I, Leverenz JB, Yearout D, Inca-Martinez M, Martinez E, Thompson TR, Cholerton BA, Hu SC, Edwards KL, Kim KS, Zabetian CP.

Mol Neurodegener. 2015 Sep 24;10:50. doi: 10.1186/s13024-015-0045-4.

27.

Clinical-pathologic correlations in vascular cognitive impairment and dementia.

Flanagan M, Larson EB, Latimer CS, Cholerton B, Crane PK, Montine KS, White LR, Keene CD, Montine TJ.

Biochim Biophys Acta. 2016 May;1862(5):945-51. doi: 10.1016/j.bbadis.2015.08.019. Epub 2015 Aug 28. Review.

28.

GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.

Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Ritz B, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson-Hiller AL, Goldman JG, Stebbins GT, Bernard B, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Tsuang D, Huston H, Yearout D, Hu SC, Cholerton BA, Montine TJ, Edwards KL, Zabetian CP.

Mov Disord. 2016 Jan;31(1):95-102. doi: 10.1002/mds.26359. Epub 2015 Aug 21.

29.

Association of cognitive domains with postural instability/gait disturbance in Parkinson's disease.

Kelly VE, Johnson CO, McGough EL, Shumway-Cook A, Horak FB, Chung KA, Espay AJ, Revilla FJ, Devoto J, Wood-Siverio C, Factor SA, Cholerton B, Edwards KL, Peterson AL, Quinn JF, Montine TJ, Zabetian CP, Leverenz JB.

Parkinsonism Relat Disord. 2015 Jul;21(7):692-7. doi: 10.1016/j.parkreldis.2015.04.002. Epub 2015 Apr 14.

30.

Long Acting Intranasal Insulin Detemir Improves Cognition for Adults with Mild Cognitive Impairment or Early-Stage Alzheimer's Disease Dementia.

Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S.

J Alzheimers Dis. 2015;45(4):1269-70. doi: 10.3233/JAD-159002. No abstract available.

PMID:
25869922
31.

Cognitive profile of LRRK2-related Parkinson's disease.

Srivatsal S, Cholerton B, Leverenz JB, Wszolek ZK, Uitti RJ, Dickson DW, Weintraub D, Trojanowski JQ, Van Deerlin VM, Quinn JF, Chung KA, Peterson AL, Factor SA, Wood-Siverio C, Goldman JG, Stebbins GT, Bernard B, Ritz B, Rausch R, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Mata IF, Hu SC, Montine KS, Johnson C, Montine TJ, Edwards KL, Zhang J, Zabetian CP.

Mov Disord. 2015 Apr 15;30(5):728-33. doi: 10.1002/mds.26161. Epub 2015 Feb 4.

32.

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.

Liu C, Cholerton B, Shi M, Ginghina C, Cain KC, Auinger P; Parkinson Study Group DATATOP Investigators, Zhang J.

Parkinsonism Relat Disord. 2015 Mar;21(3):271-6. doi: 10.1016/j.parkreldis.2014.12.027. Epub 2015 Jan 5.

33.

Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia.

Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S.

J Alzheimers Dis. 2015;44(3):897-906. doi: 10.3233/JAD-141791. Erratum in: J Alzheimers Dis. 2015;45(4):1269-70.

PMID:
25374101
34.

APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.

Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Hurtig HI, Van Deerlin VM, Ritz B, Rausch R, Rhodes SL, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson AL, Espay AJ, Revilla FJ, Devoto J, Hu SC, Cholerton BA, Wan JY, Montine TJ, Edwards KL, Zabetian CP.

JAMA Neurol. 2014 Nov;71(11):1405-12. doi: 10.1001/jamaneurol.2014.1455.

35.

People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance.

Burdick DJ, Cholerton B, Watson GS, Siderowf A, Trojanowski JQ, Weintraub D, Ritz B, Rhodes SL, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Srivatsal S, Edwards KL, Montine TJ, Zabetian CP, Leverenz JB.

Mov Disord. 2014 Sep;29(10):1258-64. doi: 10.1002/mds.25924. Epub 2014 Jul 29.

36.

Evaluation of mild cognitive impairment subtypes in Parkinson's disease.

Cholerton BA, Zabetian CP, Wan JY, Montine TJ, Quinn JF, Mata IF, Chung KA, Peterson A, Espay AJ, Revilla FJ, Devoto J, Watson GS, Hu SC, Leverenz JB, Edwards KL.

Mov Disord. 2014 May;29(6):756-64. doi: 10.1002/mds.25875. Epub 2014 Apr 7.

37.

Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.

Stewart T, Liu C, Ginghina C, Cain KC, Auinger P, Cholerton B, Shi M, Zhang J; Parkinson Study Group DATATOP Investigators.

Am J Pathol. 2014 Apr;184(4):966-975. doi: 10.1016/j.ajpath.2013.12.007. Epub 2014 Mar 11.

38.

Insulin, cognition, and dementia.

Cholerton B, Baker LD, Craft S.

Eur J Pharmacol. 2013 Nov 5;719(1-3):170-179. doi: 10.1016/j.ejphar.2013.08.008. Epub 2013 Sep 23. Review.

39.

Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics.

Cholerton BA, Zabetian CP, Quinn JF, Chung KA, Peterson A, Espay AJ, Revilla FJ, Devoto J, Watson GS, Hu SC, Edwards KL, Montine TJ, Leverenz JB.

J Parkinsons Dis. 2013;3(2):205-14. doi: 10.3233/JPD-130189.

40.

Neuropathologic correlates of cognition in a population-based sample.

Cholerton B, Larson EB, Baker LD, Craft S, Crane PK, Millard SP, Sonnen JA, Montine TJ.

J Alzheimers Dis. 2013;36(4):699-709. doi: 10.3233/JAD-130281.

41.

Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease.

Claxton A, Baker LD, Wilkinson CW, Trittschuh EH, Chapman D, Watson GS, Cholerton B, Plymate SR, Arbuckle M, Craft S.

J Alzheimers Dis. 2013;35(4):789-97. doi: 10.3233/JAD-122308.

42.

Neuropsychologic assessment in collaborative Parkinson's disease research: a proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and the University of Washington.

Watson GS, Cholerton BA, Gross RG, Weintraub D, Zabetian CP, Trojanowski JQ, Montine TJ, Siderowf A, Leverenz JB.

Alzheimers Dement. 2013 Sep;9(5):609-14. doi: 10.1016/j.jalz.2012.07.006. Epub 2012 Nov 16.

43.

Insulin and Alzheimer's disease: untangling the web.

Craft S, Cholerton B, Baker LD.

J Alzheimers Dis. 2013;33 Suppl 1:S263-75. Review.

PMID:
22936011
44.

Insulin and sex interactions in older adults with mild cognitive impairment.

Cholerton B, Baker LD, Trittschuh EH, Crane PK, Larson EB, Arbuckle M, Saucedo HH, McCurry SM, Bowen JD, McCormick WC, Craft S.

J Alzheimers Dis. 2012;31(2):401-10. doi: 10.3233/JAD-2012-120202.

45.

Insulin resistance and pathological brain ageing.

Cholerton B, Baker LD, Craft S.

Diabet Med. 2011 Dec;28(12):1463-75. doi: 10.1111/j.1464-5491.2011.03464.x. Review.

PMID:
21974744
46.

High-intensity physical activity modulates diet effects on cerebrospinal amyloid-β levels in normal aging and mild cognitive impairment.

Baker LD, Bayer-Carter JL, Skinner J, Montine TJ, Cholerton BA, Callaghan M, Leverenz JB, Walter BK, Tsai E, Postupna N, Lampe J, Craft S.

J Alzheimers Dis. 2012;28(1):137-46. doi: 10.3233/JAD-2011-111076.

47.

Cognitive response to estradiol in postmenopausal women is modified by high cortisol.

Baker LD, Asthana S, Cholerton BA, Wilkinson CW, Plymate SR, Green PS, Merriam GR, Fishel MA, Watson GS, Cherrier MM, Kletke ML, Mehta PD, Craft S.

Neurobiol Aging. 2012 Apr;33(4):829.e9-20. doi: 10.1016/j.neurobiolaging.2011.07.002. Epub 2011 Aug 19.

48.

Effects of varying diagnostic criteria on prevalence of mild cognitive impairment in a community based sample.

Trittschuh EH, Crane PK, Larson EB, Cholerton B, McCormick WC, McCurry SM, Bowen JD, Baker LD, Craft S.

J Alzheimers Dis. 2011;25(1):163-73. doi: 10.3233/JAD-2011-101821.

49.

Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer's disease.

Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A, Cholerton BA, Plymate SR, Fishel MA, Watson GS, Duncan GE, Mehta PD, Craft S.

J Alzheimers Dis. 2010;22(2):569-79. doi: 10.3233/JAD-2010-100768.

50.

Statin users without an APOE-epsilon4 allele have increased insulin resistance.

VanFossen BT, Watson GS, Baker LD, Rhoads KW, Cholerton BA, Reger MA, Plymate SR, Schellenberg G, Craft S.

J Alzheimers Dis. 2010;19(4):1149-53. doi: 10.3233/JAD-2010-1319.

Supplemental Content

Loading ...
Support Center